{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:38:59Z","timestamp":1764916739903,"version":"3.46.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The prognosis for patients with refractory\/relapsed diffuse large B-cell lymphoma (R\/R DLBCL) is dismal. Recurrence in R\/R DLBCL is mostly determined by antigen loss or mutation and the limited\n                      <jats:italic>in vivo<\/jats:italic>\n                      survival of chimeric antigen receptor (CAR) T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A 38-year-old female patient was diagnosed with left breast DLBCL in March 2018. After undergoing immunochemotherapy, autologous stem cell transplantation, and radiotherapy, she relapsed in May 2019. The peripheral blood (PB) morphology showed that 36% of cells were classified as unknown. The bone marrow (BM) smear showed 71% of abnormal lymphocytes. BM flow cytometric (FCM) analysis revealed 70.24% abnormal phenotype of mature B lymphocytes. The patient\u2019s abnormal karyotype was complex, and the 17th chromosome was missing. The p53 gene deletion (which accounted for approximately 82%) was revealed by fluorescence\n                      <jats:italic>in situ<\/jats:italic>\n                      hybridization (FISH) investigation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Autologous CD19 CAR T cells were infused after lymphodepletion chemotherapy with cyclophosphamide and fludarabine. The patient experienced Grade I cytokine release syndrome (CRS) and achieved complete remission (CR). The genetic susceptibility gene test results suggested that the patient had potential susceptibility gene mutations for hematological tumors; therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was conducted as consolidation therapy. Unfortunately, the patient relapsed 5 months after allo-HSCT. Then, the patient received sequential pseudoallogeneic CAR20\/22\/19 T-cell therapy. The patient is currently at 4 years after allo-CAR-T treatment with BM morphology CR, negative minimal residual disease, complete donor chimerism, and no graft versus host disease (GVHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that pseudoallogeneic CAR-T therapy was safe and effective in patients with DLBCL who experienced relapse after allo-HSCT. Sequential administration of CAR20\/22\/19 T cells may have reduced the antigen escape relapse in DLBCL. For patients with DLBCL relapse after allo-HSCT, larger trials are required to validate the safety and effectiveness of pseudoallogeneic CAR-T therapy as well as its ability to lower the rate of antigen escape relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1687478","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:29:00Z","timestamp":1764916140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential pseudoallogeneic CAR20\/22\/19 T-cell therapy in patient with diffuse large B-cell lymphoma relapse after allo-HSCT: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaomei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Defeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02120-7","article-title":"Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis","volume":"38","author":"Ren","year":"2024","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12672-025-01958-w","article-title":"Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review","volume":"16","author":"Berhan","year":"2025","journal-title":"Discov Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02006-3","article-title":"Clinical relevance of MYC\/BCL2 expression and cell of origin in patients with diffuse large B-cell lymphoma treated with autologous transplant","volume":"58","author":"Al-Juhaishi","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30895","article-title":"C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional \u201chits\u201d and outcomes with subsequent therapy","volume":"123","author":"Epperla","year":"2017","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3153","article-title":"CAR T-cell therapy in large B cell lymphoma","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/jpm11121345","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma: a look at the approved and emerging therapies","volume":"11","author":"Sawalha","year":"2021","journal-title":"J Pers Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11912-023-01403-7","article-title":"Allogeneic hematopoietic stem cell transplant for diffuse large B-cell lymphoma: evolving role in the era of CAR T-cell therapy","volume":"25","author":"Hilal","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.3390\/cancers13184664","article-title":"CAR-T after stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies","volume":"13","author":"Bartol\u00f3-Ibars","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17544","article-title":"Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells","volume":"195","author":"Sanber","year":"2021","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17121","article-title":"Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed\/refractory large B-cell lymphoma","volume":"192","author":"Lutf","year":"2021","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06150-8","article-title":"Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation","volume":"104","author":"Kubo","year":"2025","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.04.063","article-title":"Sequential CD19-20 CAR T-cell therapy for refractory\/relapsed diffuse large B-cell lymphoma","volume":"17","author":"Xue","year":"2025","journal-title":"Cytotherapy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell Malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005278","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell Malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.jtct.2021.08.012","article-title":"CD19\/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03198-7","article-title":"Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review","volume":"146","author":"Du","year":"2020","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1687478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:29:00Z","timestamp":1764916140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1687478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2025.1687478"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1687478","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1687478"}}